NCELNewcelX Ltd.
NCEL
NewcelX Ltd.5,959
Mkt Cap
$16.89MVolume
11,645.0052W High
$30.8052W Low
$1.83PE Ratio
-0.18NCEL Fundamentals
Price
$3.16Prev Close
$3.18Open
$3.2450D MA
$2.96Beta
0.66Avg. Volume
73,740.81EPS (Annual)
-$2.16P/B
0.47Rev/Employee
$0.00$5.46
Michel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock
NLS Pharmaceutics Ltd. (NASDAQ:NCEL - Get Free Report) Director Michel Revel acquired 54,545 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $2.75 per share, with a total value of $149,998.75. Following the completion of the acquisition, the...
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.read more...
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance...
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR...
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and...
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression...
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes...
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in...
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute NewcelX Strengthens Scientific Advisory Board...
NewcelX CEO Issues Letter to Shareholders
NewcelX CEO Issues Letter to Shareholders NewcelX CEO Issues Letter to Shareholders PR Newswire ZURICH, Nov. 4, 2025 ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss...
<
1
2
...
>
Compact View
Not available
Not available